CORR Insights®: Should the Use of Biologic Agents in Patients With Renal and Lung Cancer Affect Our Surgical Management of Femoral Metastases?

摘要

Decisions about the role of surgery and the most-appropriate bone fixation or reconstruction methods for a patient with osseous metastases often depend on the patient’s response to systemic oncologic treatment and prognosis for survival. Lung and renal cell carcinoma are among the most-common malignancies to metastasize to long bones, and osseous metastases are associated with a poorer prognosis for survival. But over the past decade, the increasing availability of systemic biologic agents, particularly receptor tyrosine kinase inhibitors and immunotherapy agents, has improved the life expectancy of many of these patients [ , ].